These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

534 related items for PubMed ID: 2941960

  • 1. A new association of ethinylestradiol (0.035 mg) cyproterone acetate (2 mg) in the therapy of polycystic ovary syndrome.
    Falsetti L, Dordoni D, Gastaldi C, Gastaldi A.
    Acta Eur Fertil; 1986; 17(1):19-25. PubMed ID: 2941960
    [Abstract] [Full Text] [Related]

  • 2. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome.
    Falsetti L, Galbignani E.
    Contraception; 1990 Dec; 42(6):611-9. PubMed ID: 2150631
    [Abstract] [Full Text] [Related]

  • 3. [Clinical use of antiandrogens in the female].
    Moltz L, Schwartz U, Hammerstein J.
    Gynakologe; 1980 Mar; 13(1):1-17. PubMed ID: 6299908
    [Abstract] [Full Text] [Related]

  • 4. Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on clinical signs of androgenization, hormone profile and ovarian size in patients with polycystic ovary syndrome.
    Prelević GM, Würzburger MI, Balint-Perić L, Puzigaća Z.
    Gynecol Endocrinol; 1989 Dec; 3(4):269-80. PubMed ID: 2516704
    [Abstract] [Full Text] [Related]

  • 5. [Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg of cyproterone acetate (Diane 35)].
    Spona J, Huber J, Schmidt JB.
    Geburtshilfe Frauenheilkd; 1986 Jul; 46(7):435-8. PubMed ID: 3093307
    [Abstract] [Full Text] [Related]

  • 6. Weight change and androgen levels during contraceptive treatment of women affected by polycystic ovary.
    Vrbikova J, Dvorakova K, Hill M, Starka L.
    Endocr Regul; 2006 Dec; 40(4):119-23. PubMed ID: 17201585
    [Abstract] [Full Text] [Related]

  • 7. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.
    Lemay A, Dodin S, Turcot L, Déchêne F, Forest JC.
    Hum Reprod; 2006 Jan; 21(1):121-8. PubMed ID: 16199428
    [Abstract] [Full Text] [Related]

  • 8. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J, Zhu Y, Jiang Y, Cao Y.
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [Abstract] [Full Text] [Related]

  • 9. Treatment of hirsutism and acne in women with two combinations of cyproterone acetate and ethinylestradiol.
    Cremoncini C, Vignati E, Libroia A.
    Acta Eur Fertil; 1976 Dec; 7(4):299-314. PubMed ID: 140576
    [Abstract] [Full Text] [Related]

  • 10. Effects of a cyproterone-containing oral contraceptive on hormonal levels in polycystic ovarian disease.
    Calaf-Alsina J, Rodriguez-Espinosa J, Cabero-Roura A, Lenti-Paoli O, Mora-Brugues J, Esteban-Altirriba J.
    Obstet Gynecol; 1987 Feb; 69(2):255-8. PubMed ID: 2949170
    [Abstract] [Full Text] [Related]

  • 11. Cyproterone acetate - ethinylestradiol treatment of hirsutism, acne, seborrhea and alopecia.
    Nardi M, De Aloysio D, Busacchi P, Flamigni C.
    Acta Eur Fertil; 1975 Jun; 6(2):153-65. PubMed ID: 127497
    [Abstract] [Full Text] [Related]

  • 12. [Management of virilization with an antiandrogen-containing contraceptive].
    Apró G, Sas M.
    Orv Hetil; 1981 Jul 26; 122(30):1821-4. PubMed ID: 6458007
    [Abstract] [Full Text] [Related]

  • 13. Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
    Uras R, Orrù M, Pani F, Marotto MF, Pilloni M, Guerriero S, Etzi R, Zedda P, Sorge R, Lello S, Melis GB, Paoletti AM.
    Contraception; 2010 Aug 26; 82(2):131-8. PubMed ID: 20654753
    [Abstract] [Full Text] [Related]

  • 14. Gonadotropin-releasing hormone agonist (GnRH-A) in hirsutism.
    Falsetti L, Pasinetti E, Ceruti D.
    Acta Eur Fertil; 1994 Aug 26; 25(5):303-6. PubMed ID: 7660719
    [Abstract] [Full Text] [Related]

  • 15. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
    van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R.
    Cutis; 2002 Apr 26; 69(4 Suppl):2-15. PubMed ID: 12096825
    [Abstract] [Full Text] [Related]

  • 16. [Clinical experience with Diane-35, currently the lowest dose antiandrogenic hormonal ovulation inhibitor, in mild to moderative androgenization in the female].
    Kaiser E.
    Geburtshilfe Frauenheilkd; 1986 Oct 26; 46(10):738-42. PubMed ID: 2948866
    [Abstract] [Full Text] [Related]

  • 17. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
    Panidis D, Georgopoulos NA, Piouka A, Katsikis I, Saltamavros AD, Decavalas G, Diamanti-Kandarakis E.
    Gynecol Endocrinol; 2011 Aug 26; 27(8):587-92. PubMed ID: 20836726
    [Abstract] [Full Text] [Related]

  • 18. Ethinylestradiol-chlormadinone acetate combination for the treatment of hirsutism and hormonal alterations of normal-weight women with polycystic ovary syndrome: evaluation of the metabolic impact.
    Guido M, Romualdi D, Campagna G, Ricciardi L, Bompiani A, Lanzone A.
    Reprod Sci; 2010 Aug 26; 17(8):767-75. PubMed ID: 20595709
    [Abstract] [Full Text] [Related]

  • 19. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.
    Falsetti L, Pasinetti E.
    Acta Obstet Gynecol Scand; 1995 Jan 26; 74(1):56-60. PubMed ID: 7856434
    [Abstract] [Full Text] [Related]

  • 20. [Treatment of moderately severe virilism of women with Diane and Androcur 10].
    Döring HF, Ilgner M.
    Z Hautkr; 1983 May 15; 58(10):761-7. PubMed ID: 6224353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.